Nplex biosciences develops protein profiling technology. The company is using nanotechnology, software and an open-platform approach to build technology to measure higher numbers of proteins simultaneously as lower cost. Their technology has applications in drug development and diagnostics. The company was launched by bioengineers at McGill University and is an alumnus of Creative Descruction Lab.
Nplex bioscences with the laboratory of David Juncker at McGill University developed a next-generation affinity-based proteomics for ELISA, termed nELISA. ELISA (enzyme-linked immunosorbent assay) is a technique for detecting and quantifying peptides, proteins, antibodies and hormones in a plate-based assay. The researchers developed a miniaturized ELISA that can be massively multiplexed without cross-reactivity. The technology uses barcoded beads that can be read out in high-throughput using flow cytometry. The team includes Milad Dagher of nplex biosciences and Thomas Durcan and Edward Fon at McGill University. The groups plans to develop a market-ready 150-plex nELISA sandwich immunoassay multiplex for use in cell-based drug screening. It will be applied to phenotype the secretome in a 5000-compound screen of iPSC-derived astrocytes from a Parkinson’s disease patient.